An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Ramucirumab (Primary) ; Abemaciclib; Merestinib
- Indications Colorectal cancer; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 15 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2017 Planned End Date changed from 1 May 2018 to 1 Jan 2019.